share_log

Pfizer | 8-K: Pfizer Announced That It Is Beginning the Process of Finding a Successor for Dr. Mikael Dolsten

Pfizer | 8-K: Pfizer Announced That It Is Beginning the Process of Finding a Successor for Dr. Mikael Dolsten

辉瑞 | 8-K:辉瑞宣布正在开始为Mikael Dolsten博士寻找继任者
美股sec公告 ·  07/10 16:15
Moomoo AI 已提取核心信息
Pfizer Inc. has announced the commencement of a search for a new Chief Scientific Officer as Dr. Mikael Dolsten, the current Chief Scientific Officer and President of Pfizer Research & Development, prepares to step down. Dr. Dolsten, who has had a notable career spanning over 15 years at Pfizer, will remain in his role until a successor is appointed and a proper transition is completed. The company has begun an external search for his replacement and expects Dr. Dolsten to stay with the company until at least February 28, 2025. This transition was reported in a Form 8-K filed with the SEC, dated July 9, 2024, with the report signed the following day by Margaret M. Madden, Senior Vice President and Corporate Secretary of Pfizer.
Pfizer Inc. has announced the commencement of a search for a new Chief Scientific Officer as Dr. Mikael Dolsten, the current Chief Scientific Officer and President of Pfizer Research & Development, prepares to step down. Dr. Dolsten, who has had a notable career spanning over 15 years at Pfizer, will remain in his role until a successor is appointed and a proper transition is completed. The company has begun an external search for his replacement and expects Dr. Dolsten to stay with the company until at least February 28, 2025. This transition was reported in a Form 8-K filed with the SEC, dated July 9, 2024, with the report signed the following day by Margaret M. Madden, Senior Vice President and Corporate Secretary of Pfizer.
辉瑞公司宣布开始寻找新的首席科学官,现任首席科学官和研发总裁Mikael Dolsten博士准备辞职。Dolsten博士在辉瑞公司的杰出职业跨足了15多年,他将在接任者被任命并完成适当的过渡之前继续担任该职位。公司已经开始外部搜索他的继任者,预计Dolsten博士将至少留在公司直到2025年2月28日。这一过渡在一份提交给美国证券交易委员会的8-k文件中报道,文件于2024年7月9日签署,签署者是辉瑞公司高级副总裁兼公司秘书Margaret m. Madden。
辉瑞公司宣布开始寻找新的首席科学官,现任首席科学官和研发总裁Mikael Dolsten博士准备辞职。Dolsten博士在辉瑞公司的杰出职业跨足了15多年,他将在接任者被任命并完成适当的过渡之前继续担任该职位。公司已经开始外部搜索他的继任者,预计Dolsten博士将至少留在公司直到2025年2月28日。这一过渡在一份提交给美国证券交易委员会的8-k文件中报道,文件于2024年7月9日签署,签署者是辉瑞公司高级副总裁兼公司秘书Margaret m. Madden。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息